https://www.news1.kr/articles/5017542
Securing Cases of Partial Response (PR) in Initial Patients
ABION (CEO Shin Young khee, KRX 203400) announced that it is experiencing positive momentum in the global Phase 2 clinical trial of its non-small cell lung cancer treatment, ABN401, and progressing smoothly with the cohort 1 study.
ABN401, developed by ABION, is a non-small cell lung cancer therapy targeting c-MET mutations and is currently undergoing global Phase 2 clinical trials in Korea and the United States. Cohort 1 of the Phase 2 trial is a monotherapy for NSCLC patients with exon 14 skipping mutation. The first patient was administrated in January.
The company stated that based on the excellent safety and efficacy results obtained from Phase 1, the Phase 2 trial is enrolling patients faster than expected, leading to an acceleration in the dosing process. Particularly noteworthy is the absence of any significant adverse events or reports of side effects to date, further raising expectations. The company has also secured cases of partial response (PR) in two early patients, who showed measurable efficacy after three weeks of treatment.
Recently, ABION presented preclinical results for the ABN401 brain metastasis model and KRAS mutation model at the American Association for Cancer Research (AACR). The company plans to focus more on the ongoing Phase 2 cohort 1 trial, aiming to derive interim results for mid-term reporting.
Meanwhile, ABION successfully raised funds by issuing convertible bonds (CB) worth KRW 21 billion, with the purpose of utilizing them for the global clinical development of ABN401. Despite the volatile global interest rate market, Korean Investment Partners, Atinum Investment, StarQuest Asset Management, and Lapgenomics participated in this funding, demonstrating their confidence in the company’s potential.
An ABION representative stated, “The global clinical trials are progressing at an accelerated pace, and we anticipate significant achievements, such as technology transfer, in the near future. Therefore, we have secured funds to facilitate more stable negotiations,” and added, “We will make every effort to produce positive outcomes with the successful funding.”
